Nycomed Gmbh

Byk Gulden Lomberg Chemische Fabrik Gmbh

Altana Pharma Ag

Takeda Gmbh

Byk Gulden Chemische Fabrik Gmbh

Astrazeneca Ab

Rango Dietrich

Rudolf Linder

Hartmut Ney

George A Sachs

Klaus Eistetter

Marc Schiller

Isabel Anstett-Klein

Manfred Hartmann

Sabine Schaefer-Preuss

Sabine Schäfer-Preuss

Isabel Anstett

Dosage forms for oral administration of a PDE 4 inhibitor whose solubility is slight are described. They contain PVP as binder.

Oral dosage form containing a PDE 4 inhibitor as an active ingredient and polyvinylpyrrolidon as excipient

Dosage forms for oral administration of the magnesium salt of (S)-pantoprazole are described.

Dosage form containing (S)-pantoprazole as active ingredient

Lyophilized pantoprazole preparations which are obtainable by freeze-drying of an aqueous solution of pantoprazole, ethylenediamine tetraacetic acid and/or a suitable salt thereof, and sodium hydroxide and/or sodium carbonate are disclosed. The preparations have advantageous properties when reconstituted for injection.

Freeze-dried pantoprazole preparation and pantoprazole injection

Dosage forms for the oral administration of the magnesium salt of pantoprazole are described.

Dosage form containing pantoprazole as active ingredient

The invention relates to an oral administration form for pyridin-2-ylmethylsulfinyl-1H-benzimidazoles and their salts, which comprises the active compound together with tablet disintegrants and is provided with a film coating customary per se for sustained-release compositions.

Oral administration form for pyridin-2-ylmethylsulfinyl-1H benzimidazoles

Oral dosage form containing a PDE 4 inhibitor as an active ingredient and polyvinylpyrrolidone as excipient

The present invention relates to the field of pharmaceutical technology and describes a pharmaceutical preparation in the form of a paste comprising an acid-labile active ingredient, in particular an acid-labile proton pump inhibitor. The invention also relates to processes for producing the paste. The paste is particularly suitable for administering acid-labile active ingredients to animals or to people who have difficulty taking solid dosage forms such as tablets or capsules.

Pharmaceutical preparation in the form of a paste comprising an acid-labile active ingredient

The present invention relates to the field of pharmaceutical technology and describes a novel advantageous preparation for an active ingredient. The novel preparation is suitable for producing a large number of pharmaceutical dosage forms. In the new preparation, an active ingredient is present essentially uniformly dispersed in an excipient matrix composed of one or more excipients selected from the group of fatty alcohols, triglycerides, partial triglycerides and fatty acid esters.

Pharmaceutical preparation comprising an active dispersed on a matrix

Novel administration forms and preparations for acid-labile active compounds are described. The novel administration forms contain individual active compound units, the active compound being present in the active compound units in a matrix made of a mixture comprising at least one fatty alcohol and at least one solid paraffin, in a matrix made of a mixture of a triglyceride and at least one solid paraffin or in a matrix made of a mixture comprising at least one fatty acid ester and at least one solid paraffin. In particular, the active compound units are microspheres which can be produced by prilling.

Preparation and administration form comprising an acid-labile active compound

Novel administration forms and preparation for acid-labile active compounds are described. The novel administration forms contain individual active compound units, the active compound being present in the active compound units in a matrix made of a mixture comprising at least one fatty alcohol and at least one solid paraffin, in a matrix made of a mixture of a triglyceride and at least one solid paraffin or in a matrix made of a mixture comprising at least one fatty acid ester and at least one solid paraffin. In particular, the active compound units are microspheres which can be produced by prilling.

Binder

Oral administration form for pyridin-2-ylmethylsulfinyl-1H-benzimidazoles

The present invention relates to the field of pharmaceutical technology and describes a novel pharmaceutical preparation in the form of a suspension comprising an acid-labile active ingredient, in particular an acid-labile proton pump inhibitor. The invention also relates to processes for producing the suspension. The suspension is particularly suitable for administering acid-labile active ingredients to people who have difficulty taking solid dosage forms such as tablets or capsules.

Growing community of inventors

Constance, Germany

Rango Dietrich